deltatrials
Active Not Recruiting PHASE1 INTERVENTIONAL 1-arm NCT03602157

Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL

Phase I Study of the Administration of T Lymphocytes Co-Expressing the CD30 Chimeric Antigen Receptor (CAR) and CCR4 for Relapsed/Refractory CD30+ Hodgkin Lymphoma and Cutaneous T-Cell Lymphoma

Sponsor: National Cancer Institute (NCI)

Conditions Cutaneous Anaplastic Large Cell Lymphoma Cutaneous Lymphoma Cutaneous T Cell Lymphoma Gray Zone Lymphoma Immune System Diseases Immunoproliferative Disorders Lymphatic Diseases Lymphoma Lymphomatoid Papulosis Lymphoproliferative Disorders Mycosis Fungoides Neoplasms Sezary Syndrome
Interventions ALTCAR.CD30 cells ATLCAR.CD30.CCR4 cells Bendamustine Fludarabine
Updated 22 times since 2018 Last updated: Jan 2, 2026 Started: Dec 12, 2018 Primary completion: Dec 16, 2025 Completion: Nov 4, 2039
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Cutaneous Anaplastic Large Cell Lymphoma and Cutaneous Lymphoma and is currently ongoing. National Cancer Institute (NCI) leads this study, which shows 22 recorded versions since 2018 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Aug 2018 – ~Sep 2018 · 31 days · monthly snapshot~Sep 2018 – ~Oct 2018 · 30 days · monthly snapshot~Oct 2018 – ~Dec 2018 · 2 months · monthly snapshot~Dec 2018 – ~Feb 2019 · 2 months · monthly snapshot~Feb 2019 – ~Jul 2019 · 5 months · monthly snapshot~Jul 2019 – ~Feb 2020 · 7 months · monthly snapshot~Feb 2020 – ~May 2020 · 3 months · monthly snapshot~May 2020 – ~Jan 2021 · 8 months · monthly snapshot~Jan 2021 – ~Sep 2021 · 8 months · monthly snapshot~Sep 2021 – ~Jan 2022 · 4 months · monthly snapshot~Jan 2022 – ~Jun 2022 · 5 months · monthly snapshot~Jun 2022 – ~Dec 2022 · 6 months · monthly snapshot~Dec 2022 – ~Oct 2023 · 10 months · monthly snapshot~Oct 2023 – ~May 2024 · 7 months · monthly snapshot~May 2024 – ~Jul 2024 · 2 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Nov 2024 · 2 months · monthly snapshot~Nov 2024 – ~Feb 2025 · 3 months · monthly snapshot~Feb 2025 – ~Apr 2025 · 59 days · monthly snapshot~Apr 2025 – ~Jan 2026 · 9 months · monthly snapshot~Jan 2026 – ~Feb 2026 · 31 days · monthly snapshot~Feb 2026 – present · 4 months · monthly snapshot

Change History

22 versions recorded

  1. Feb 2026 — Present [monthly]

    Active Not Recruiting PHASE1

  2. Jan 2026 — Feb 2026 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

  3. Apr 2025 — Jan 2026 [monthly]

    Recruiting PHASE1

  4. Feb 2025 — Apr 2025 [monthly]

    Recruiting PHASE1

  5. Nov 2024 — Feb 2025 [monthly]

    Recruiting PHASE1

▶ Show 17 earlier versions

  1. Sep 2024 — Nov 2024 [monthly]

    Recruiting PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE1

  3. May 2024 — Jul 2024 [monthly]

    Recruiting PHASE1

  4. Oct 2023 — May 2024 [monthly]

    Recruiting PHASE1

  5. Dec 2022 — Oct 2023 [monthly]

    Recruiting PHASE1

  6. Jun 2022 — Dec 2022 [monthly]

    Recruiting PHASE1

  7. Jan 2022 — Jun 2022 [monthly]

    Recruiting PHASE1

  8. Sep 2021 — Jan 2022 [monthly]

    Recruiting PHASE1

  9. Jan 2021 — Sep 2021 [monthly]

    Recruiting PHASE1

  10. May 2020 — Jan 2021 [monthly]

    Recruiting PHASE1

  11. Feb 2020 — May 2020 [monthly]

    Recruiting PHASE1

  12. Jul 2019 — Feb 2020 [monthly]

    Recruiting PHASE1

  13. Feb 2019 — Jul 2019 [monthly]

    Recruiting PHASE1

  14. Dec 2018 — Feb 2019 [monthly]

    Recruiting PHASE1

  15. Oct 2018 — Dec 2018 [monthly]

    Recruiting PHASE1

    Status: Not Yet Recruiting → Recruiting

  16. Sep 2018 — Oct 2018 [monthly]

    Not Yet Recruiting PHASE1

  17. Aug 2018 — Sep 2018 [monthly]

    Not Yet Recruiting PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Cancer Institute (NCI)
  • Stand Up To Cancer
  • UNC Lineberger Comprehensive Cancer Center
Data source: UNC Lineberger Comprehensive Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations